Advanced Oncotherapy PLC Total Voting Rights and Significant Shareholdings (3945O)
January 29 2019 - 4:38AM
UK Regulatory
TIDMAVO
RNS Number : 3945O
Advanced Oncotherapy PLC
29 January 2019
29 January 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Total Voting Rights and Director and Significant
Shareholdings
Advanced Oncotherapy plc (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
confirms that the 25,000,000 Subscription Shares issued pursuant to
the Subscription announced on 21 December 2018 were admitted to
trading on AIM ("Admission") on 28 January 2019.
The Company's issued share capital now consists of 194,566,092
Ordinary Shares with one voting right each. The Company does not
hold any Ordinary Shares in treasury. Therefore, the total number
of Ordinary Shares in the Company with voting rights is
194,566,092. This figure may be used by shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Directors' and Significant Shareholdings
Set out below are details of the Directors' beneficial
shareholdings and, in so far as the Company has been made aware,
shareholdings of certain new Significant shareholders following
Admission, being DNCA Investments and Barrymore Investments
Ltd.
Shareholder Number of Shares % of issued
share capital
Liquid Harmony Limited 45,000,000 23.13%
----------------- ---------------
DNCA Investments 12,000,000 6.17%
----------------- ---------------
Barrymore Investments Ltd* 7,905,721 4.06%
----------------- ---------------
Mr Michael S Bradfield (Non-executive
Director) 7,080,740 3.64%
----------------- ---------------
Dr Michael Sinclair & Family (Chairman) 6,594,660 3.39%
----------------- ---------------
AB Segulah** 6,488,789 3.34%
----------------- ---------------
Dr P N Plowman (Non-executive Director) 3,930,304 2.02%
----------------- ---------------
Dr Enrico C Vanni (Non-executive
Director) 1,926,361 0.99%
----------------- ---------------
Mr Nicolas Serandour (Chief Executive
Officer) 1,760,467 0.90%
----------------- ---------------
Professor Stephen Myers (Non-executive
Director) 783,902 0.40%
----------------- ---------------
Mr Hans Van Celsing (Non-executive
Director) 30,000 0.02%
----------------- ---------------
*Barrymore Investments Ltd is a company under the control of
Seamus Mulligan.
**Gabriel Urwitz (Non-executive Director) is a director of AB
Segulah
Defined terms in this announcement shall have the same meaning
as in the announcement of 21 December 2018 unless otherwise defined
herein.
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 20 3617 8728
Chairman
Nicolas Serandour, CEO
Stockdale Securities (Nomad &
Joint Broker)
Antonio Bossi / David Coaten Tel: +44 20 7601 6100
Stifel Nicolaus Europe (Joint
Broker)
Jonathan Senior Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR) Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 54 1 893 / Mob: +44
7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the
treatment of cancer, which harnesses the very best in modern
technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva,
focuses on the development of a proprietary proton accelerator -
LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates
protons to the energy levels achieved in legacy machines but in a
compact and truly modular unit, offering significant cost
advantages. LIGHT also delivers proton beams in a way that
facilitates greater precision and electronic control, which are not
achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology, offering better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton or particle therapy and
actively seeks working relationships with providers of these
innovative technologies. Through these relationships, the Company
will remain the prime provider of cutting edge, cost-effective
systems for particle therapy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVREANFNADKNEEF
(END) Dow Jones Newswires
January 29, 2019 04:38 ET (09:38 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024